AstraZeneca’s MedImmune subsidiary has reached an agreement with US-based pharmaceutical major Pfizer for the potential cancer treatment tremelimumab.

MedImmune will assume global development rights to the CTLA-4 monoclonal antibody, whereas Pfizer will retain the rights to use the drug alongside combination therapies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

MedImmune Research and Development head Bahija Jallal said: "Adding another immunotherapeutic approach to our oncology pipeline… exemplifies our continued commitment to embracing this new era of cancer."

Tremelimumab has had something of a chequered past, with Pfizer discontinuing a late-stage trial of the drug in 2008 following a review of interim data that showed the drug would not out-perform standard chemotherapy.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now